“I’m going to irritate a lot of people today,” began Dee Edington, keynote speaker on health management as a serious business strategy, at the Benefits Canada 2012 Benefits & Pension Summit. Drawing on his experience as director of the University of Michigan Health Management Research Center, Edington had a lot to say about what doesn’t […]
What keeps plan sponsors awake at night? According to Joyal, soaring costs and retirement benefits rank high on the list.
The growing impact of high-cost specialty drugs, coupled with shifting roles for health practitioners, calls for stakeholders to work together to improve drug plan efficiencies. But how?
Magna International Inc., a global vehicle part manufacturer and assembler with a workforce of 104,000, has a decentralized management structure that allows every division to run as a separate entity, said Arthur Fabbro, the organization’s director of total compensation.
While Canadian drug innovators have to follow an arduous process when filing for regulatory approval for traditional small molecules, generic manufacturers “don’t have to prove as much, so the process is abbreviated—although they have to wait until the patents for the original drug and a data-exclusivity period have expired,”
Moderator Suzanne Lepage, a Toronto-based private plan strategist, launched the discussion by asking panellists what principles they followed when making decisions about drugs.
Barbara Martinez, a principal with Mercer, reported on the findings of the organization’s 2011 survey of Canadian private drug plans.
Steve Moffatt, senior vice-president of sales and marketing with Green Shield Canada, questioned plan sponsors’ ongoing tendency to have their drug plans provide full coverage in today’s financially constrained landscape.
One morning, at age 21, Jeff Aarssen found himself unable to get out of bed.
When an employee becomes mentally ill, where do the employer’s responsibilities begin and end? And what role does the employee play in achieving a successful recovery?